University of Minnesota. Driven to Discover.
The analysis is a key part of a federal review of controversial studies on H5N1 and other pathogens.
The lastest patient, a foreign man in Riyadh, contracted the disease in a healthcare setting.
The candidate vaccine, given as nose drops, produced a strong immune response.
The NSABB plans to release final recommendations in spring 2016.
Sierra Leone reports no cases after having 5 last week, and new funds for drugs and vaccines are announced.
Three new cases are noted, and an NIH study shows promising vaccine results in animals.
As cases drop slightly, vaccine trials suffer from lack of patients. Also, the NIH announces a trial involving survivors.
Even hospitals that had done preparedness drills faced challenges, and the threat consumed a lot of resources.
The first two phase 1 trials of VSV-EBOV vaccine show good immune responses.
Funding will be used to continue trials of BCX4430 and prepare for its large-scale manufacture.
Get CIDRAP news and other free newsletters.
Sign up now»
Unrestricted financial support provided by
Grant support for ASP provided by
Become an underwriter»
CIDRAP - Center for Infectious Disease Research and PolicyOffice of the Vice President for Research, University of Minnesota, Minneapolis, MN
© 2019 Regents of the University of Minnesota. All rights reserved.The University of Minnesota is an equal opportunity educator and employer.